Journal Scans
Denosumab and Bone-Metastasis-Free Survival In Men With Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial
Denosumab and Bone–Metastasis-Free Survival In Advanced Prostate Cancer
MR Smith, F Saad, R Coleman, N Shore, C Goessl, et al
Yes
20111015
2011 Nov 15
Lancet
Denosumab and Bone-Metastasis-Free Survival In Men With Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial
Lancet. 2011 Nov 15;[Epub Ahead of Print], MR Smith, F Saad, R Coleman, N Shore, C Goessl, et al
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer.Methods: In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castration-resistant prostate cancer at high...
